The Utsunomiya plant will be crucial in establishing Chugai as one of the largest potential commercial suppliers of treatments such as MRA, a humanised anti-IL-6 receptor monoclonal antibody (Atlizumab) indicated for rheumatoid arthritis.
-
Bioreactors installed at the phase one facility. -
Granocyte, an important product for Chugai, is produced at the Utsunomiya plant. -
A microscopic view of multiple myeloma, a condition the new MRA antibody... -
A healthy red blood cell count. One of Chugai's products is erythropoietin, a... -
The Utsunomiya plant will be crucial in establishing Chugai as one of the... -
Some of the process equipment supplied by Amersham Biosciences.
Twitter